Search | Clinical Trials Finder

Conditions: Fetal Growth Abnormality, Amniotic Fluid; Disorder
Interventions: Point-of-care ultrasound (POC-US), Routine antenatal care, Formal ultrasound; Diagnostic Test
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions: A166; Drug
Lead sponsor: Klus Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more

Conditions: Intracerebral Hemorrhage
Interventions: recombinant activated factor VII, placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Phoenix, Arizona • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Breast Cancer
Interventions: cisplatin, everolimus, paclitaxel, laboratory biomarker analysis; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 4
States / cities: Chattanooga, Tennessee • Jackson, Tennessee • Knoxville, Tennessee + 1 more

Conditions: Ovarian Cancer, Solid Tumors
Interventions: OSI-906, Paclitaxel; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 8
States / cities: Scottsdale, Arizona • Orange, California • Lafayette, Indiana + 5 more

Conditions: Plexiform Neurofibromas, NF1
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 100 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
Interventions: enfortumab vedotin, pembrolizumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 29
States / cities: Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more

Conditions: Acromegaly, Growth Hormone Deficiency, Pituitary Disease
Interventions: Recombinant human growth hormone, Saline; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Abnormality
Interventions: skin biopsy; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 12 Months and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Overweight and Obesity
Interventions: Intervention; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 1 Day to 1 Month
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Diabetic Macular Edema
Interventions: Teprotumumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Beverly Hills, California • St. Petersburg, Florida • Omaha, Nebraska

Conditions: Anemia, Undernutrition, Underweight, Stunting, Maternal Malnutrition
Interventions: Maternal Nutrition Behavior change; Behavioral
Lead sponsor: International Food Policy Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Growth Hormone Insensitivity Syndrome (GHIS), Laron Syndrome
Interventions: rhIGF-I/rhIGFBP-3; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 2 Years to 18 Years
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelodysplastic Syndromes
Interventions: Omacetaxine, Azacitidine, G-CSF; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
Interventions: ABBV-221; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
Interventions: TH-4000 (Tarloxotinib); Drug
Lead sponsor: Rain Oncology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Santa Rosa, California • Aurora, Colorado + 8 more

Conditions: HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions: Rosiglitazone, Recombinant human growth hormone + rosiglitazone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 4
States / cities: New York, New York

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: ganetespib, paclitaxel, trastuzumab, pertuzumab; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: New York, New York

Conditions: Normal Healthy Volunteers
Interventions: Fulvestrant, Anastrozole, Placebo, Somatostatin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Growth Hormone Disorder, Adult Growth Hormone Deficiency
Interventions: somapacitan, somatropin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 23 Years to 79 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 23 more

Conditions: Short Stature
Interventions: Norditropin; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 2 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Idiopathic Short Stature, Failure to Thrive
Interventions: Not listed
Lead sponsor: Tripler Army Medical Center; Federal
Eligibility: 3 Months to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Tripler AMC, Hawaii

Conditions: Advanced Solid Tumors
Interventions: IMC-A12; Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: X-linked Hypophosphatemia, Hypophosphatemic Rickets, Hypophosphatemic Rickets, X-Linked Dominant
Interventions: Calcitriol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 3 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Serial Third Trimester Abdominal Circumference and Amniotic Fluid Measurements Versus Routine Care

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

The Spot Sign for Predicting and Treating ICH Growth Study

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

Study of Plexiform Neurofibromas in Neurofibromatosis Type 1

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency

Vascular Malformations and Abnormalities of Growth

Califormula Study: Calibrated Formula Feeding to Optimize Infant Growth

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Maternal Nutrition Interventions in Uttar Pradesh, India

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer

Impact of Endogenous E2 on SSI and GH Rebound

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency

Ghrelin Levels in Children With Poor Growth

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Calcitriol Monotherapy for X-Linked Hypophosphatemia